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Introduction
Inward Na+ currents (INa–) carried by voltage-gated (NaV) channels underlie the initiation and propagation 
of  action potentials in the atria and ventricles (1). Functional NaV channels reflect the assembly of  the 4 
homologous domains (DI–DIV) in the pore-forming (α) subunit that are connected by intracellular linkers. 
Each domain contains 6 transmembrane segments (S1–S6). S1–S4 form the voltage-sensing domains (VSDs). 
The VSDs undergo conformational changes upon membrane depolarization, which open the pore (S5–S6), 
enabling inward Na+ flux (2). Native myocardial NaV channels function in macromolecular protein complex-
es, containing many regulatory and anchoring proteins that differentially affect channel function and localiza-
tion based on the cell type (3). NaVβ subunits are essential components of  these macromolecular complexes. 
There are 5 different types of  NaVβ subunits, NaVβ1, NaVβ1B, NaVβ2, NaVβ3, and NaVβ4. NaVβ1, NaVβ1B, 
and NaVβ3 interact with the NaV α subunits noncovalently; NaVβ2 and NaVβ4 are linked covalently through 
the formation of  disulfide bonds (4). NaVβ1, NaVβ2, NaVβ3, and NaVβ4 are transmembrane proteins, whereas 
NaVβ1B is secreted (5). Consistent with a crucial role for NaVβ subunits in maintaining normal heart func-
tion, variants in the genes encoding NaVβ subunits have been linked to cardiac rhythm disorders, including 
Brugada syndrome, long QT syndrome, and sick sinus syndrome (4). However, recent evidence suggests that 
SCN1B may not be a monogenic cause of  Brugada or sudden arrhythmic death syndrome (6, 7). NaVβ1 and 
NaVβ1B, splice variants of  SCN1B, are the dominant NaVβ subunits in the mammalian heart (8).
Although NaVβ subunits were first cloned from a rat brain in the 1990s (9), the molecular interactions 
between NaVα-NaVβ subunits have remained elusive until recently. The cryo-electron microscopy structures 
of  the NaV1.4-NaVβ1 and the NaV1.7-NaVβ1-NaVβ2 complexes suggest that NaVβ1 coassembles with NaV α 
Native myocardial voltage-gated sodium (NaV) channels function in macromolecular complexes 
comprising a pore-forming (α) subunit and multiple accessory proteins. Here, we investigated 
the impact of accessory NaVβ1 and NaVβ3 subunits on the functional effects of 2 well-known 
class Ib antiarrhythmics, lidocaine and ranolazine, on the predominant NaV channel α subunit, 
NaV1.5, expressed in the mammalian heart. We showed that both drugs stabilized the activated 
conformation of the voltage sensor of domain-III (DIII-VSD) in NaV1.5. In the presence of NaVβ1, the 
effect of lidocaine on the DIII-VSD was enhanced, whereas the effect of ranolazine was abolished. 
Mutating the main class Ib drug-binding site, F1760, affected but did not abolish the modulation 
of drug block by NaVβ1/β3. Recordings from adult mouse ventricular myocytes demonstrated 
that loss of Scn1b (NaVβ1) differentially affected the potencies of lidocaine and ranolazine. In vivo 
experiments revealed distinct ECG responses to i.p. injection of ranolazine or lidocaine in WT and 
Scn1b-null animals, suggesting that NaVβ1 modulated drug responses at the whole-heart level. In 
the human heart, we found that SCN1B transcript expression was 3 times higher in the atria than 
ventricles, differences that could, in combination with inherited or acquired cardiovascular disease, 
dramatically affect patient response to class Ib antiarrhythmic therapies.
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subunits near the domain-III VSD (DIII-VSD) (10–12). However, the recent structure of  NaV1.5 revealed 
that NaVβ1 interacts with the predominant cardiac NaV α subunit at a distinct site or sites that are charac-
terized by weaker binding and an unresolvable NaV1.5-NaVβ1 complex (13). This difference in comparison 
with channels encoded by other NaV α subunits is partially due to the unique N-linked glycosylation of  
NaV1.5 that hinders its interaction with the Ig domain of  NaVβ1 (13). Intriguingly, NaVβ1 and NaVβ3 are 
highly homologous except in the Ig domains. Previously, optical tracking of  the NaV1.5 VSDs using volt-
age-clamp fluorometry (VCF) revealed that the NaVβ3 subunit modulates both the DIII and the DIV-VSDs, 
whereas NaVβ1 only modulates the DIV-VSD conformational dynamics (14, 15). Fluorescence quenching 
experiments showed that the DIII-VSD is in close proximity to NaVβ3 but not NaVβ1 (14). These results 
suggest that NaVβ1 and NaVβ3 regulate the NaV1.5 DIII-VSD differently.
The conformational changes in the VSDs are not only important for regulating channel gating; they are 
also essential for modulating channel interactions with drugs, including those that bind to the pore domain, 
such as local anesthetics (16). Previously, VCF and gating current recordings showed that when lidocaine 
blocks NaV1.4 channels, it stabilizes the DIII-VSD in its activated conformation (17). Moreover, we recent-
ly demonstrated that alteration of  DIII-VSD conformational changes caused by long QT syndrome 3 vari-
ants leads to channels with different mexiletine sensitivities (18, 19).
Class I antiarrhythmics modulate cardiomyocyte excitability via NaV channel targeting. Class Ib mole-
cules, such as lidocaine, ranolazine, and mexiletine, specifically modulate the late component of  INa, result-
ing in shortening of  the action potential duration in ventricular cardiomyocytes (20). Lidocaine has long 
been used to manage ventricular arrhythmias in hospital settings (21). Ranolazine has been shown to be 
effective in controlling various cases of  atrial fibrillation (AF) (22–24), particularly paroxysmal AF (25, 26). 
Recently, the RAID trial demonstrated that ranolazine also marginally lowered the risk of  recurrent ven-
tricular tachycardia and ventricular fibrillation in high-risk patients with implanted cardioverter-defibrilla-
tors (27). Although both drugs are commonly prescribed for several arrhythmias, their efficacies are highly 
variable. Thus, it remains an important task to understand the determinants of  channel-drug interactions 
that contribute to this variability.
In the experiments presented here, we aimed to understand the molecular mechanisms whereby nonco-
valently bound NaVβ subunits modulate the interaction of  class Ib antiarrhythmics with myocardial NaV1.5 
channels. We further investigated the physiological significance of  this modulation by assessing ranolazine 
and lidocaine drug blockade of  native NaV currents in mouse ventricular myocytes, probing the mRNA 
expression levels of  NaVβ subunits in human hearts and detailing the in vivo electrophysiological pheno-
types evident in the cardiac-specific Scn1b-null mouse (28). Our results showed a critical role for β subunits 
in differentially modulating the efficacy of  lidocaine and ranolazine, implying that patient-to-patient differ-
ences in β subunit expression are likely to have a significant impact on therapeutic outcomes.
Results
Both lidocaine and ranolazine alter NaV1.5 DIII-VSD dynamics. Previous studies demonstrated that lidocaine 
shifts the activation of  the DIII-VSD in rat NaV1.4 channels encoded by Scn4a and prominent in skeletal 
muscle in the hyperpolarizing direction (16, 29, 30). Recent findings showed that a class Ib antiarrhythmic, 
mexiletine, which is similar in structure to lidocaine, also affects the DIII-VSD conformation in NaV1.5 
channels (18, 19). The DIII-VSD effect also determines the tonic and use-dependent properties of  class Ib 
drugs (18, 19). Taken together, these observations suggest that factors that alter drug effects on the DIII-
VSD would be expected to have an impact on therapeutic efficacy.
To explore this hypothesis, we first used VCF to assess the effects of  2 class Ib antiarrhythmics, lido-
caine and ranolazine (Figure 1A), on the DIII-VSD in heterologously expressed human NaV1.5 channels, 
which are encoded by SCN5A, the predominant NaV α subunit expressed in the mammalian heart (Figure 
1, B and C). When we expressed the NaV1.5 α subunit alone in Xenopus oocytes, we observed a hyperpolar-
izing shift (ΔV1/2 = –24.8 ± 9.4 mV, P = 0.03) in the DIII fluorescence-voltage (F-V) curve on exposure to 
10 mM lidocaine, and a similar shift (ΔV1/2 = –30.7 ± 7.5 mV, P = 0.05) on application of  4 mM ranolazine, 
suggesting that both lidocaine and ranolazine stabilize the DIII-VSD in its activated conformation (Figure 
1, B–D). The observation of  similar effects on the DIII-VSD caused by both drugs is not surprising because 
they share similar molecular structures (Figure 1A), shown previously to interact with residue F1760 in 
DIV-S6 (20, 31). In addition, however, the effects of  lidocaine and ranolazine are not identical. Lidocaine, 
for example, induced a hyperpolarizing shift in the DIV F-V curve, an effect not observed with ranolazine 
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(Figure 1, B–D), suggesting that despite sharing common binding motifs on the NaV1.5 α subunit, the dis-
tinct chemical structures of  lidocaine and ranolazine (Figure 1A) uniquely regulate DIV-VSD dynamics.
NaVβ1 and NaVβ3 differentially modulate lidocaine/ranolazine effects on the DIII-VSD. We have previously 
shown that both NaVβ1 and NaVβ3 alter DIII-VSD dynamics during NaV1.5 channel gating (14). Thus, we 
hypothesized that these NaVβ subunits will also alter the effects of  class Ib antiarrhythmics on the DIII-
VSD. To test this hypothesis, we coexpressed NaV1.5 with the NaVβ1 or NaVβ3 subunit and measured DIII-
VSD and DIV-VSD conformational changes before and after lidocaine or ranolazine application.
When we coexpressed NaV1.5 with NaVβ1, we observed distinct DIII-VSD responses to lidocaine and 
ranolazine. Lidocaine induced a greater hyperpolarizing shift (ΔV1/2 = –57.6 ± 10.2 mV, P = 0.01) in DIII-
FV (Figure 2A) when NaVβ1 was present compared with the NaV1.5 α subunit expressed alone. Exposure 
to ranolazine, in marked contrast, did not result in a significant DIII-FV shift (ΔV1/2 = –12.8 ± 16.8 mV, P 
= 0.53) (Figure 2C), suggesting that the DIII-VSD was free to move in NaV1.5 channels in the presence of  
NaVβ1 to recover to the resting state. Although the presence of  NaVβ1 increased the lidocaine effect on the 
DIII-VSD, NaVβ1 coexpression eliminated the ranolazine effect.
Strikingly, coexpression with the NaVβ3 subunit resulted in opposite effects on lidocaine and ranolazine 
interaction with the DIII-VSD. Upon lidocaine block, the DIII F-V curve was minimally shifted to more 
hyperpolarized potentials (ΔV1/2 = –25.3 ± 10.9 mV, P = 0.13) (Figure 2B), while the ranolazine effect on 
the DIII-VSD was potentiated, resulting in a larger hyperpolarizing shift in the DIII F-V (ΔV1/2 = 58.0 ± 
4.7 mV, P < 0.001) (Figure 2D).
Additionally, coexpression of  NaVβ1 or NaVβ3 with NaV1.5 both eliminated the hyperpolarizing shift 
in the DIV F-V curve that was observed with the NaV1.5 α subunit expressed alone (Figure 2, A and B), 
suggesting that the NaVβ1 and NaVβ3 subunits similarly altered lidocaine’s effect on the DIV-VSD.
These results demonstrated that NaVβ subunits differentially regulated lidocaine and ranolazine inter-
actions with the DIII-VSD in heterologously expressed NaV1.5 channels. Specifically, NaVβ1 enhanced 
the effect of  lidocaine but decreased the effect of  ranolazine on the DIII-VSD activation, whereas NaVβ3 
coexpression had the opposite effects on both drugs. The altered drug interactions with the DIII-VSD 
resulted in an enhanced block by lidocaine and reduced block by ranolazine when the NaV1.5 α subunit was 
coexpressed with NaVβ1 compared with NaVβ3 (Figure 3C).
To determine whether the differential modulation of  lidocaine and ranolazine block by NaVβ1 
and NaVβ3 is dependent on the main local anesthetic binding site F1760 (20, 31) (Figure 3A), we 
assessed drug blockade of  the F1760A-mutant NaV1.5 channel in the presence of  NaVβ1 or NaVβ3. 
As expected, the F1760A-mutant channels exhibited much reduced block by lidocaine and ranola-
zine compared with the WT channels (Figure 3, C and D). However, application of  10 mM lidocaine 
or 4 mM ranolazine still caused significant tonic block (TB) and use-dependent block (UDB) of  the 
F1760A channels (Figure 3, D and E). TB reflects resting-state drug block, while UDB requires prior 
channel opening (32). In contrast to the WT channels, the hyperpolarizing shift in the DIII F-V upon 
lidocaine or ranolazine block was not observed with the F1760A-mutant channels (Figure 3B). The 
F1760A mutation also eliminated NaVβ1 and NaVβ3 modulation of  TB by lidocaine and ranolazine as 
well as UDB by lidocaine (Figure 3, D and E). However, despite the absence of  a major drug-binding 
site, coexpression of  NaVβ3 still caused stronger UDB by ranolazine compared with NaVβ1 (Figure 
3E). These results suggest that the effects of  NaVβ1/β3 on lidocaine and ranolazine block are affected 
by the F1760 anesthetic binding site but are not completely dependent on it.
Loss of  Scn1b expression in mouse cardiomyocytes does not affect NaV channel gating. To further investigate how 
noncovalent NaVβ1/β1B subunits affect the cardiomyocyte response to class Ib antiarrhythmics, we utilized 
the cardiac-specific Scn1b-null mouse model (Scn1bfl/fl/Myh6-cre) described previously (28). First, we com-
pared INa in left ventricular (LV) myocytes acutely dissociated from adult Scn1b cardiac-specific null and WT 
mice. Peak INa density was increased by 28% in Scn1b-null compared with WT LV myocytes (Scn1b-null: 81.3 
± 3.6 pA/pF, WT: 63.9 ± 5.2 pA/pF, P = 0.017). An increase in INa density in cardiac-specific Scn1b-null 
isolated from juvenile mice was previously reported (28). Consistent with the increase in current density, we 
also observed increased Scn5a transcript expression in the ventricles (and atria) of  the Scn1b-null compared 
with WT mice (Supplemental Figure 1; Supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.143092DS1). Other than increasing peak current density, Scn1b deletion did not 
measurably alter other NaV channel gating properties in ventricular cardiomyocytes (Figure 4A), including 
the voltage dependences of  channel activation (Figure 4B), steady-state inactivation (Figure 4B), and/or the 
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kinetics of  channel recovery from inactivation (Figure 4C). Notably, deleting Scn1b did not measurably alter 
the expression of  other NaVβ subunits (Supplemental Figure 1). These results, although contrary to previous-
ly reported effects of  NaVβ1 on INa in heterologous expression systems, are consistent with results obtained 
in studies on global and cardiac-specific Scn1b-null mice (28, 33).
Increased block of  INa by ranolazine but reduced block by lidocaine in adult Scn1b-null mouse ventricular myocytes. 
Even though NaV channel gating was not measurably affected in cardiac-specific Scn1b-null myocytes, we 
went on to determine whether the loss of  Scn1b affects the responses of  native NaV channels to class Ib anti-
arrhythmics. We examined the effects of  lidocaine and ranolazine on TB and UDB of  INa in LV myocytes 
isolated from WT and cardiac-specific Scn1b-null mice.
The TB produced by 100 μM lidocaine was similar in WT and Scn1b-null LV myocytes (Figure 5A). 
In marked contrast, the block of  late INa by lidocaine was significantly reduced in Scn1b-null LV myocytes 
(Figure 5B). There was also an approximately 3-fold reduction in lidocaine UDB in Scn1b-null compared 
with WT LV myocytes (WT: EC50UDB = 9.3 μM, Scn1b-null EC50UDB = 24.8 μM) (Figure 5E). Conversely, 
ranolazine increased TB, late INa block, and UDB in Scn1b-null compared with WT adult mouse LV myo-
cytes (Figure 5, C, D, and F) (WT: EC50UDB = 53.3 μM, Scn1b-null EC50UDB = 36.0 μM). The differences in 
UDB by lidocaine between WT and Scn1b-null myocytes depended on the frequency and duration of  the 
depolarizing pulses (Figure 5G). In response to 10 μM lidocaine, INa from Scn1b-null showed decreased UDB 
compared with WT myocytes at 10 Hz (25 ms duration) and 2 Hz (400 ms duration) but not 5 Hz (25 ms 
duration) (Figure 5G). In contrast, in response to 10 μM ranolazine, INa in WT myocytes showed increased 
UDB compared with Scn1b-null myocytes at all 3 frequencies (Figure 5H). Both lidocaine and ranolazine 
are known to cause a hyperpolarizing shift in the voltage dependence of  steady-state inactivation of  cardiac 
INa (24, 34), indicating that drug binding promotes channel inactivation at more hyperpolarized membrane 
potentials. Therefore, we also compared the voltage dependence of  INa inactivation in WT and Scn1b-null LV 
Figure 1. Class Ib antiarrhythmics lidocaine and ranolazine alter NaV1.5 VSD conformations. (A) Chemical structures of lidocaine and ranolazine. (B) Voltage 
dependence of the steady-state fluorescence (F-V curves) from the 4 domains (DI-V215C, DII-S805C, DIII-M1296C, DIV-S1618C) of NaV1.5 before and after 10 
mM lidocaine. Lidocaine was used at 10 mM to produce a robust tonic block (TB). In the presence of lidocaine, fluorescence was measured when TB reached 
more than 70%. Lidocaine induced a hyperpolarizing shift in both the DIII and DIV F-V curves. (C) F-V curves from the 4 domains of NaV1.5 before and after 
4 mM ranolazine. Similar to the lidocaine experiment (B), in the presence of ranolazine, the fluorescence was measured when TB reached more than 70%. 
Ranolazine caused a hyperpolarizing shift in the DIII but not in the DIV F-V curve. (D) Schematic showing effects of lidocaine and ranolazine on the DIII- and 
DIV-VSDs; note that each VSD is represented by a single S4 segment for clarity. Lidocaine caused both the DIII and the DIV VSDs to stabilize in the activated 
conformation, whereas ranolazine only stabilized the DIII-VSD in the activated position. Each data set represents mean ± SEM values from 4–6 cells.
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Figure 2. Coexpression with NaVβ1 or NaVβ3 differentially modulates the effect of lidocaine and ranolazine on the DIII-VSD. (A) In the presence of 
NaVβ1, the hyperpolarizing shift in the DIII F-V curve produced by lidocaine was enhanced compared with the Nav1.5 α subunit expressed alone. In marked 
contrast, the DIV F-V curve was not affected by lidocaine with NaVβ1 present. (B) In contrast with NaVβ1 (A), the hyperpolarized shift in the DIII F-V curve 
induced by lidocaine was eliminated when NaVβ3 was coexpressed. Similar to NaVβ1, however, the DIV F-V curve was minimally affected by lidocaine. (C) 
In the presence of NaVβ1, the effect of ranolazine on the DIII F-V curve was eliminated, whereas the DIV F-V was slightly hyperpolarized. (D) In contrast 
with NaVβ1 (C), the hyperpolarized shift in the DIII F-V curve caused by ranolazine was enhanced when NaVβ3 was coexpressed. In the presence of NaVβ3, 
ranolazine also caused a small hyperpolarizing shift in the DIV F-V curve. Each data set represents mean ± SEM values from 4–6 cells.
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myocytes before and after lidocaine or ranolazine application. These experiments revealed 100 μM lidocaine 
induced a hyperpolarizing shift in INa inactivation in WT LV myocytes and a smaller shift in Scn1b-null LV 
myocytes (Supplemental Figure 2A). Conversely, 100 μM ranolazine induced a comparable leftward shift in 
the voltage dependence of  inactivation of  INa in WT and Scn1b-null LV myocytes (Supplemental Figure 2B).
Overall, these cellular studies revealed that in adult mouse LV myocytes, the cardiac deletion of  Scn1b 
resulted in reduced lidocaine UDB but increased ranolazine UDB. These results are consistent with our 
Figure 3. Altering the key local anesthetics’ binding site F1760 did not completely abolish NaVβ1/β3 modulations 
of ranolazine block. (A) Cryo-electron microscopy structure of human NaV1.4(11) (Protein Data Bank 6AGF) showing 
the relative locations of the F1760 residue, DIII, DIV, and NaVβ1. (B) Mutating the main local anesthetic binding residue 
F1760 to alanine (A) greatly reduced the hyperpolarizing shift in the DIII-VSD upon 10 mM lidocaine, as well as 4 mM 
ranolazine, observed in the WT channel (Figures 1 and 2). (C) Percentage of TB induced by 10 mM lidocaine and 4 mM 
ranolazine in the WT channel. The presence of NaVβ3 reduced lidocaine TB but enhanced ranolazine TB compared with 
the α-NaVβ1 complex. (D) Percentage of TB induced by 10 mM lidocaine and 4 mM ranolazine in the F1760A channel. 
In contrast to WT, NaVβ1 and NaVβ3 no longer exerted a significant effect on lidocaine and ranolazine TB. (E) UDB by 
lidocaine and ranolazine in F1760A channel coexpressed with NaVβ1 or NaVβ3. There was no change in lidocaine UDB 
comparing coexpression with NaVβ1 and NaVβ3. However, the presence of NaVβ1 caused a reduced ranolazine UDB com-
pared with NaVβ3, a phenomenon that is similar to NaVβ1’s effects on the WT channel. Each data set represents mean 
± SEM values from 3–6 cells. Unpaired 2-tailed Student’s t test was used to test significance (C–E). *P < 0.05.
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VCF data (Figures 1 and 2), suggesting that the presence of  NaVβ1 subunits enhanced lidocaine’s effects 
but reduced ranolazine’s effects on the NaV1.5 DIII-VSD. The reduced effects on the DIII-VSD are also 
consistent with the decreased UDB of  INa observed in LV myocytes (Figure 5).
Ranolazine and lidocaine induced distinct ECG phenotypes in WT and Scn1b-null mice. To understand how 
NaVβ1/β1B modulate antiarrhythmic responses at the whole-heart level, we measured surface ECGs in 
anesthetized WT and Scn1b-null mice before and after i.p. injection of  lidocaine or ranolazine (Figure 6 
and Supplemental Table 1). From the raw ECG data, we quantified several parameters that describe overall 
heart electrical functioning, including RR intervals, providing a measure of  heart rates; P wave intervals, 
representing atrial conduction; PR intervals, characterizing atrial-ventricular conduction; QRS intervals, 
revealing ventricle conduction; and QT and ST intervals, corresponding to ventricular repolarization.
We found that 20 mg/kg ranolazine caused QRS prolongation in both WT and Scn1b-null mice (Figure 
6, A and B), but that P wave and PR interval prolongation only occurred in the Scn1b-null mice (Figure 
6B). The QT interval, but not the ST interval, was also prolonged by ranolazine in Scn1b-null mice (Figure 
6B and Supplemental Figure 3). These results suggest that Scn1b deletion enhanced the inhibitory effect of  
ranolazine on cardiac conduction. Similar to the effects observed at the single myocyte level (Figures 4 and 
5) that the loss of  Scn1b enhanced TB and UDB of  INa by ranolazine, loss of  NaVβ1/β1B in Scn1b-null mice 
promoted ranolazine block, manifesting as P wave, PR, and QRS interval prolongation.
We observed that 30 mg/kg lidocaine administration increased P wave duration in WT and Scn1b-null 
mice (Figure 6, A and C). In addition, lidocaine induced prolongation of  RR, QT, and ST intervals in WT 
but not Scn1b-null mice (Figure 6C and Supplemental Figure 3). In contrast, lidocaine increased PR and 
QRS intervals in Scn1b-null mice (Figure 6C). Lidocaine injection, therefore, resulted in distinct functional 
effects in the 2 genotypes. We conducted control experiments in which we measured ECGs before and 
after injection of  PBS solution. Comparison of  baseline and post-PBS data showed that ECG parameters 
remained constant (Supplemental Figure 4).
SCN1B is differentially expressed in human atria and ventricles. The observation that loss of  Scn1b alters the 
ability of  class Ib antiarrhythmics to block NaV channels in the mouse heart suggests that the differential 
expression of  SCN1B might play an important role in regulating antiarrhythmic drug responses in humans. 
Figure 4. INa gating is similar in Scn1b-null and WT mouse LV myocytes. (A) Representative recordings of INa in WT and 
Scn1b-null mouse LV myocytes revealed similar kinetics of activation and inactivation. However, the average peak cur-
rent density was slightly (~28%) higher in Scn1b-null compared with WT. (B) Loss of NaVβ1 in Scn1b-null mouse LV myo-
cytes did not affect the voltage dependences of INa activation or steady-state inactivation. (C) Loss of NaVβ1 in Scn1b-null 
mouse LV myocytes also did not affect the time course of INa recovery from inactivation. Each data set represents mean 
± SEM values from 6–9 cells.
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Figure 5. Scn1b-null LV myocytes show reduced lidocaine but enhanced ranolazine responses. (A) TB of INa by 100 μM lidocaine was slightly reduced in 
Scn1b-null compared with WT mouse LV myocytes. (B) Percentage of late INa block by 100 μM lidocaine was markedly lower in Scn1b-null compared with 
WT mouse LV myocytes. Late INa was measured 30 ms after the onset of the depolarizing voltage step. (C) TB of INa by 100 μM ranolazine was greater 
in Scn1b-null compared with WT mouse LV myocytes. (D) Percentage of late INa block by 100 μM ranolazine was greater in Scn1b-null compared with 
WT mouse LV myocytes. (E) Dose-response curve (top) and example traces (bottom) for UDB of INa by lidocaine. UDB was examined by measuring INa 
evoked in response to 8 repetitive (400 ms duration) depolarizations presented at 2 Hz, which determines the initial rate of UDB. The EC50 for UDB of INa 
by lidocaine was lower in WT compared with Scn1b-null suggesting that NaVβ1 enhances the sensitivity to lidocaine. (F) Dose-response curve (top) and 
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To begin to explore this hypothesis, we examined mRNA expression levels of  the genes SCN1B, SCN2B, 
SCN3B, and SCN4B encoding NaVβ subunits in human heart tissue in a recently published RNA-Seq library 
(35). These analyses revealed that in the human heart, SCN1B is the most abundant of  the NaVβ subunits 
at the transcript level and that SCN1B transcript expression is much higher in atria than in ventricles (Fig-
ure 7A). In contrast, the expression levels of  the SCN2B and SCN4B transcripts are higher in the ventricles 
than in the atria (Figure 7A). To validate the RNA-Seq findings and to determine whether both SCN1B 
splice variants, SCN1BA (NaVβ1) and SCN1BB (NaVβ1B), are differentially expressed in human atria and 
ventricles, we performed quantitative RT-PCR analyses on the same tissue samples used in the RNA-Seq 
analyses. These experiments revealed that the relative expression levels of  the 2 SCN1B splice variants were 
significantly higher in the atria compared with the ventricles (Figure 7B). Additional analyses revealed that, 
although expression of  SCN1BA was approximately 100-fold higher than SCN1BB, the expression levels of  
the 2 (SCN1BA and SCN1BB) splice variants were similar in human right and left atria and in the LV and 
right ventricle (RV) (Supplemental Figure 5).
Discussion
Although class Ib antiarrhythmics have considerable therapeutic potential, they are not broadly prescribed 
because of  proarrhythmic risks in some patients and ineffectiveness in others (36, 37). Patient or disease 
variability in class Ib drug response suggests that there are external factors that modulate drug interactions 
with the channel (37). In this study, we investigated the role of  NaV channel accessory subunits NaVβ1 and 
NaVβ3 in regulating class Ib antiarrhythmic–mediated effects on NaV1.5 channels. We demonstrated that at 
a molecular level, NaVβ1 or NaVβ3 subunit coexpression differentially altered the effects of  lidocaine and 
ranolazine on the NaV1.5 DIII-VSD. NaVβ1 enhanced lidocaine but inhibited ranolazine modulation of  the 
DIII-VSD. Conversely, NaVβ3 eliminated lidocaine modulation but increased the effect of  ranolazine on 
the DIII-VSD. Differential molecular interactions between NaV1.5 DIII-VSD and class Ib antiarrhythmic 
drugs caused by NaVβ1 subunit expression in a heterologous system translated to distinct drug blockade of  
NaV channels in WT versus Scn1b cardiac-specific null mouse cardiomyocytes. We further demonstrated 
differential effects of  lidocaine and ranolazine on the ECG phenotypes of  WT and Scn1b-null mice.
NaVβ1 and NaVβ3 subunits alter NaV1.5 channel pharmacology via the DIII-VSD. The DIII-VSD plays an 
important role in regulating NaV1.5 channel gating. It is involved in both activation and inactivation 
of  NaV channels (38, 39). Recent studies showed a correlation between DIII-VSD deactivation and the 
slow component of  recovery from inactivation, which suggests that an activated form of  the DIII-VSD 
stabilizes inactivation (39). Given that class Ib antiarrhythmics promote DIII-VSD activation, they may 
subsequently promote inactivation to induce greater levels of  UDB. We recently demonstrated that DIII-
VSD activation determines NaV1.5 channel blockade by mexiletine and affects the sensitivity of  LQT3 
variants to this drug (18), demonstrating a clear connection between the conformation of  the DIII-VSD 
and class Ib drug potency.
We previously demonstrated that NaVβ3 directly modulates the DIII-VSD, whereas NaVβ1 does not 
(14). Recent channel structures suggest that NaVβ1 associates with NaV1.7 and NaV1.4 through the DIII-
VSD, an interaction that is not conserved in NaV1.5 (10, 12, 13). In light of  these structural and functional 
data, it is plausible that NaVβ3 interacts with NaV1.5 through similar sites as illustrated in the NaV1.4/ 
NaV1.7-β1 complex, while NaVβ1 occupies a different site. Two distinct interaction mechanisms will result 
in the differential modulation of  the DIII-VSD by NaVβ1 and NaVβ3. Here, we showed that coexpression of  
the NaVβ1 or NaVβ3 subunit differentially modulated the ability of  class Ib antiarrhythmics to stabilize the 
DIII-VSD in the activated conformation, providing further evidence that in contrast to other NaV channel α 
subunits, NaVβ1 and NaVβ3 have distinct interactions with NaV1.5. The effect of  lidocaine on the DIII-VSD 
has been previously shown (14) to regulate UDB, a critical feature of  class Ib drugs, which renders them 
most potent when myocytes are being excited repeatedly during an arrhythmic event. We observed that 
ranolazine and lidocaine similarly affected NaV1.5 α subunit–encoded channels expressed in the absence 
example traces (bottom) for UDB of INa by ranolazine. In contrast to lidocaine, the EC50 for UDB by ranolazine was higher in WT compared with Scn1b-null, 
suggesting NaVβ1 reduces the effects of ranolazine. (G) Frequency-dependent UDB block of INa by 10 μM lidocaine in WT and Scn1b-null LV myocytes. UDB 
was assessed by measuring INa evoked by repetitive depolarizing pulses at 5 Hz (25 ms, 40 pulses), 10 Hz (25 ms, 40 pulses), and 2 Hz (400 ms, 8 pulses). 
Normalized currents indicate INa(last-pulse)/INa(first-pulse). (H) Frequency-dependent UDB block of INa by 10 μM ranolazine in WT and Scn1b-null LV myocytes. 
Each data set represents mean ± SEM of data from 3–5 cells. Unpaired 2-tailed Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001.
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of  the NaVβ subunits. However, with the NaVβ1 subunit present, the lidocaine effect on the DIII-VSD was 
enhanced, whereas the ranolazine effect was blunted. Conversely, NaVβ3 enhanced ranolazine-induced 
DIII-VSD stabilization while inhibiting the effect of  lidocaine. The differential regulation of  the DIII-VSD 
resulted in distinct effects on the potencies of  lidocaine and ranolazine depending on which NaVβ was pres-
ent. Thus, despite the similarity of  the chemical structures (Figure 1), the therapeutic responses to lidocaine 
and ranolazine were differentially modified by the coexpression of  the NaVβ1 or the NaVβ3 subunit.
NaVβ1/β1B modulates class Ib antiarrhythmic responses from molecular to the whole-heart level. In Xenopus 
oocytes, with VCF and cut-open voltage clamp recordings, we demonstrated that NaVβ1 coexpression 
enhanced lidocaine’s but inhibited ranolazine’s effect on the DIII-VSD, which resulted in an increased 
lidocaine but decreased ranolazine block. In addition, we observed increased UDB and late INa block by 
lidocaine but opposite effects with ranolazine in WT compared with Scn1b-null mouse LV myocytes. This 
cellular difference further led to distinct phenotypes of  the in vivo ECG recordings in response to lidocaine 
and ranolazine injections. For example, in response to ranolazine injection, the P wave duration and PR 
interval were prolonged in the Scn1b-null mice but not in the WT mice. This difference in ECG parameters 
reflects the cellular phenotype of  enhanced ranolazine block of  INa in Scn1b-null compared with WT LV 
myocytes. However, not all the ECG changes can be explained by the differences observed in myocyte INa 
recordings of  atrial and ventricular myocytes, and they may be caused by NaVβ1-mediated effects on other 
regions of  the myocardium, such as the sinoatrial and atrioventricular nodes (40). Alternatively, NaVβ1 may 
affect drug interactions with other ion channels that regulate cardiac excitation, as discussed further below.
Differential expression of  NaVβ1/β1B in human atria and ventricles and chamber-specific drug responses. Ranola-
zine was proposed as a candidate for atrial specific therapy for AF (24, 41). Studies in the canine heart 
showed that atrial and ventricular cardiomyocytes have distinct responses to ranolazine (24). In the atria, 
ranolazine prolongs the action potential duration measured at 90% repolarization (APD90) and effective 
refractory period (24). In contrast, in the ventricle, ranolazine shortens the APD90. Here, we demonstrat-
ed higher SCN1Ba (NaVβ1) and SCN1Bb (NaVβ1B) subunit mRNA expression levels in human atria com-
pared with ventricles. While we showed that NaVβ1 coexpression attenuated ranolazine block of  INa in 
both Xenopus oocytes and mouse LV myocytes, higher levels of  NaVβ1 in human atria may result in simi-
lar attenuation of  the effects of  ranolazine, thus contributing to decreased ranolazine blockade compared 
with ventricles. Notably, ranolazine is also a blocker of  KCNH2–encoded (HERG-encoded) repolarizing IKr 
channels (22). If  ranolazine blockade of  INa is reduced in atria, modulation of  IKr may dominate, resulting 
in prolongation of  APD specifically in atria. Thus, the heterogeneous expression of  NaVβ1 may play a role 
in the chamber-specific ranolazine response.
NaVβ subunit modulation of  class Ib drug effects may underlie disease-specific drug responses. A search of  
NCBI’s Gene Expression Omnibus (GEO) profile database (42) revealed that SCN1B is upregulated in isch-
emic cardiomyopathies in human heart [GEO GDS651 and GDS1362 (43)] and mouse heart failure mod-
els [GEO GDS411, GDS427 (44), and GDS3660 (45)] (Supplemental Figure 6). These data suggest that 
the expression of  NaVβ subunits can be altered in disease remodeling of  the cardiac tissue. Since late INa 
was found to be increased in the failing heart, class Ib drugs have become potential therapeutic approaches 
in targeting heart failure–related arrhythmias (46). As we have demonstrated that NaVβ can differentially 
modulate class Ib effects, upregulation of  NaVβ1 in failing tissue may alter the patient response to NaV 
channel–targeting antiarrhythmic therapies.
Differential effects of  NaVβ subunits on lidocaine and ranolazine interactions reflect distinct molecular drug-pore 
interactions. Previous work postulated that both lidocaine and ranolazine bind to common residues in the 
NaV1.5 channel pore (20, 31). However, we observed that lidocaine modulated both the DIII- and DIV-
VSDs of  NaV1.5, whereas ranolazine only affected the DIII-VSD when NaV1.5 was expressed without 
Figure 6. ECG recordings from WT and Scn1b-null mice before and after ranolazine or lidocaine injections. (A) Representative ECG recordings 
obtained from WT and Scn1b-null mice at baseline, postranolazine, and postlidocaine are presented. The postranolazine and postlidocaine data were 
recorded 10 minutes after the i.p. injections of ranolazine or lidocaine. P wave durations, PR, QRS, and QT intervals were measured as indicated in 
the insets. (B) Comparison of ECG parameters measured in WT (left panel) and Scn1b-null (right panel) mice at baseline and 10 minutes after i.p. 
injections of ranolazine injection. Ranolazine markedly prolonged the P wave duration and the PR interval in Scn1b-null but not in WT mice. (C) Com-
parison of ECG parameters measured in WT (left panel) and Scn1b-null (right panel) mice at baseline and 10 minutes after i.p. injections of lidocaine. 
Lidocaine markedly prolonged the RR interval, P wave duration, and QT interval in WT mice. In Scn1b-null mice, lidocaine also prolonged the P wave 
duration and resulted in marked prolongation of the PR and QRS intervals. Each data set represents data from 4–7 mice. The ECG parameters and 
statistical comparisons are shown in Supplemental Table 1.
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NaVβ subunits, suggesting that these compounds may present in different orientations in the channel pore. 
Recent molecular dynamics simulations shed light on the detailed binding conformations of  lidocaine and 
ranolazine within the NaV1.5 channel (47). Interestingly, these studies revealed that 2 lidocaine molecules 
can bind to the pore concurrently, one to the F1760 site and the other to the central pore (47). In contrast, 
ranolazine binds to the F1760 residue and possesses a more flexible linear structure, allowing it to interact 
with a larger area ranging from the fenestration to the selectivity filter (47). Moreover, ranolazine has a 
pKa of  7.2 (48) and lidocaine has a pKa of  7.9 (49). At physiological pH, therefore, a higher percentage of  
ranolazine molecules are expected to be uncharged compared with lidocaine. This difference will determine 
the relative percentages of  the drug molecules entering in the hydrophobic pathway through the fenestra-
tion versus the hydrophilic pathway via the intracellular gate. The presence of  NaVβ1 or NaVβ3 modulates 
DIII-VSD and DIV-VSD dynamics, which can allosterically affect the conformation of  the pore and fenes-
trations. We demonstrated that NaVβ1/β3’s modulation of  ranolazine block was not entirely dependent on 
the main local anesthetic binding site, F1760, suggesting the changes in the DIII-VSD conformation due 
to NaVβ modulation are essential for determining drug accessibility to the pore, independent of  binding. 
In contrast, eliminating the F1760 binding site abolished the effects of  NaVβ1/β3 coexpression on lido-
caine block, further suggesting that lidocaine acts through mechanisms distinct from those of  ranolazine. 
Because lidocaine and ranolazine have different stoichiometries, orientations within the pore, and entrance 
pathways, it is plausible that changing channel VSD and pore conformations in the presence of  NaVβ sub-
units can result in opposite effects on DIII-VSD interactions with these drugs.
NaVβ subunit modulation of  antiarrhythmic drug outcome beyond NaV channels. Aside from NaV channels, 
NaVβ subunits have been shown to modulate expression and gating of  various potassium channels, includ-
ing the voltage-gated KV 4.3 and the inward-rectifying Kir 2.1 channels, resulting in modifications of  2 
essential cardiac currents, the fast transient outward K+ current (Ito,f) and the inward rectifier current (IK1–) 
(50–52). Although unexplored to date, it also seems highly likely that the presence of  NaVβ subunits can 
affect KV and Kir channel pharmacology as well. Here, we showed that although single cardiac-specif-
ic Scn1b-null LV myocytes displayed attenuated inhibition of  INa by lidocaine compared with WT cells, 
enhanced PR and QRS interval prolongation was observed in Scn1b-null animals with lidocaine, suggesting 
contributions from other cardiac ionic currents.
Limitations. To assess the drug effects on VSD dynamics, we conducted the VCF experiments in Xen-
opus oocytes. Because this is a heterologous expression system and the experiments were performed at 
19°C, extrapolating the results to mammalian physiology can be difficult. However, we observed consistent 
drug-mediated modulatory effects in oocytes and in mouse LV myocytes, observations that support the 
hypothesis that the molecular mechanisms we identified with VCF are operative in mammalian systems.
Figure 7. Regional differences in SCN1B expression in human atria and ventricles. (A) Extracted RNA-Seq data, 
expressed as reads per kilobase of exon per million mapped reads, from analyses of sequencing data obtained from 
matched (n = 8) human ventricular and atrial tissue samples (44). The SCN1B transcript was the most abundant of 
the NaVβ subunits expressed in human atria and ventricles. In addition, SCN1B expression was approximately 3-fold 
higher in human atria compared with ventricles, whereas both SCN2B and SCN4B were approximately 2-fold higher in 
human ventricles than atria. (B) The differential expression of SCN1B in human atria and ventricles was confirmed by 
quantitative PCR (qPCR) analyses of the same paired human atrial and ventricular tissue samples analyzed by RNA-
Seq. In addition, qPCR analyses using primers that distinguish the 2 SCN1B variants, SCN1Ba and SCN1Bb, revealed 
that the relative expression levels of both SCN1Ba and SCN1Bb transcripts were higher in the atria than the ventricles. 
Paired 2-tailed Student’s t test was used to test significance. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
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We were only able to show that the expression of  SCN1B was enriched in the atria compared with 
ventricles in the human heart at the transcript level. Although we attempted to examine protein expression 
levels directly, none of  the available anti-NaVβ1 antibodies detect NaVβ1 proteins in mouse or human cardi-
ac tissues. Since it is currently not possible to perform gene editing or to use siRNA-mediated knockdown 
strategies in native human myocytes, we were not able to explore the functional effects of  NaVβ1 on class 
Ib drugs in human myocytes directly.
Conclusions. In summary, we have demonstrated roles for noncovalently linked NaVβ subunits in reg-
ulating antiarrhythmic drug effects from molecular interactions to whole-heart phenotypes. Our results 
elucidated the differential regulation of  NaV1.5 channels by 2 class Ib agents, lidocaine and ranolazine, by 
NaVβ1 and NaVβ3 subunits. The unique expression profile of  NaVβ subunits in the human heart suggests 
chamber-dependent responses to these 2 compounds. Our findings provide crucial insights into strategies 
for improving the clinical outcomes of  patients treated with class Ib agents for different forms of  arrhyth-
mias. Moreover, NaVβ1 expression is upregulated in heart failure, and it remains unexplored whether NaVβ 
subunit expression is affected in other heart pathologies. This knowledge will be highly valuable in estab-
lishing disease-specific approaches to personalize arrhythmia treatment with lidocaine and ranolazine 
because known changes in β subunit expression will have predictable effects on therapeutic outcomes.
Methods
Experimental animals. Adult (8–15 weeks old) male and female WT and cardiac-specific Scn1b-null C57BL/6J 
mice were used in the experiments here. Cardiac-specific Scn1b-null mice were generated by crossing Scn1bfl 
mice (27) with B6.FVBTg(Myh6-cre)2182Mds/J mice (The Jackson Laboratory), which express Cre recombi-
nase driven by the α-myosin heavy chain promoter. Mice were genotyped by PCR analyses of  genomic (tail) 
DNA using primers targeting sequences external to the loxP sites, as well as primers targeting Cre recom-
binase, as previously described (27). Because of  the breeding strategy required to generate cardiac-specific 
Scn1b-null C57BL/6J mice, WT littermates were not generated. The WT mice used in the experiments pre-
sented here, therefore, were not littermate controls; rather they were WT C57BL/6J mice from our colony. 
Additional control experiments, however, were conducted on Scn1bfl and B6.FVBTg(Myh6-cre)2182Mds/J 
mice, which were determined to be indistinguishable electrophysiologically from WT C57BL/6J animals. 
Xenopus oocyte harvests were performed as described previously (53).
Cut-open VCF. VCF experiments were conducted using 4 previously developed NaV1.5 channel constructs 
(DI: V215C, DII: S805C, DIII: M1296C, DIV: S1618C) (53). Capped mRNAs were synthesized with the 
mMESSAGE mMACHINE T7 transcription kit (Life Technologies, Thermo Fisher Scientific) from the lin-
earized pMAX vectors. VCF construct mRNA was injected alone or coinjected with SCN1B or SCN3B mRNA 
into Xenopus oocytes as previously described (14). VCF experiments were performed 4–6 days after injection. 
The recording setup and labeling protocol used were described previously (14, 53–55). Lidocaine hydrochloride 
and ranolazine dihydrochloride were dissolved in extracellular recording solution and then further diluted to 10 
mmol/L and 4 mmol/L, respectively. Both drugs were manually perfused into the extracellular solution cham-
ber in the cut-open voltage clamp setup. Fluorescence signals and currents were analyzed as previously described 
(18). V1/2 values reported were quantified from the Boltzmann function fit, y = 1/(1 + exp [V – V1/2]/k). Because 
the DIII F-V curve, especially under drug treatment conditions, did not saturate at the lowest voltage recorded 
(–160 mV), the fit was performed by fixing 0 at –200 mV. Because of the lack of saturation at the most negative 
potentials measured, the estimated V1/2 for DIII F-V is likely to be higher than the actual V1/2 value.
ECG recordings. Surface ECG recordings were obtained as previously described from mice anesthetized 
by i.p. injection of  avertin (0.25 mg/kg; MilliporeSigma) (56). Baseline ECGs were recorded, and animals 
were weighed. For injections, drugs were dissolved in 250 μL PBS. Lidocaine or ranolazine was then injected 
at a dosage of  30 mg/kg or 20 mg/kg, respectively. Different animals were used for lidocaine or ranolazine 
injections. Between recordings, mice were kept on a heating pad maintained at 37°C ± 0.5°C. Postinjection 
ECGs were recorded at 5 minutes, 10 minutes, 15 minutes, 20 minutes, and 30 minutes. Peak responses were 
observed at 10 minutes, which was subsequently selected as the time point for ECG analysis.
RR, PR, and QT intervals, as well as P and QRS durations, were measured and compiled using 
Clampfit 10.3 (Molecular Devices) and GraphPad Prism. Note that QT intervals shown in figures were 
not corrected because several recent studies have shown that QT intervals in anesthetized mice do not 
vary with heart rate (57, 58). Similar differences were revealed, however, when corrected QT intervals 
were compared (Supplemental Table 1).
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Isolation of  adult mouse cardiomyocytes. Myocytes were isolated from adult (8 to 12 weeks old) WT or 
Scn1b-null mice as previously described (59). Briefly, hearts were isolated and perfused retrogradely through 
the aorta with a Ca2+-free Earle’s balanced salt solution containing 0.8 mg/mL type II collagenase (Worth-
ington). After perfusion, the LV free wall was dissected and minced. The tissue pieces were then triturated 
to provide individual LV myocytes. Dispersed cells were then filtered and resuspended in Medium199 (Gib-
co, Thermo Fisher Scientific), plated on laminin-coated (MilliporeSigma) glass coverslips, and maintained 
in a 95% air/5% CO2 incubator at 37°C.
Whole-cell NaV current (INa) recordings were obtained from isolated LV myocytes at room tempera-
ture (22°C–24°C) within 5–6 hours of  isolation using a Dagan 3900A amplifier interfaced to a Digidata 
1332A A/D converter (Axon) using pClamp 10.2 (Axon). Recording pipettes contained the following (in 
mmol/L): 120 glutamic acid, 120 CsOH, 10 HEPES, 0.33 MgCl2, 20 tetraethylammonium chloride (TEA-
Cl), 4 Mg-ATP, 5 glucose, and 5 EGTA (pH adjusted to 7.3 with CsOH); pipette resistances were 1.5–3.0 
MΩ. The bath solution contained the following (in mM): 20 mM NaCl, 110 mM TEACl, 4 KCl, 2 MgCl2, 1 
CaCl2, 10 HEPES, and 10 glucose (pH 7.4; 300 mOsm).
Electrophysiological data were acquired at 10–20 KHz, and signals were low-pass-filtered at 5 
kHz before digitization and storage. After the formation of  a giga-seal (>1 GΩ) and establishment 
of  the whole-cell configuration, brief  (10 ms) ± 10 mV voltage steps from a holding potential (HP) 
of  –70 mV were presented to allow measurements of  whole-cell membrane capacitances (Cm), input 
resistances (Rin), and series resistances (Rs). In each cell, Cm and Rs were compensated electronically 
by approximately 85%; voltage errors resulting from uncompensated Rs were less than 2 mV and were 
not corrected. Leak currents were always less than 50 pA and were not corrected. Whole-cell INa were 
evoked in response to 40 ms voltage steps to potentials between –60 and +40 mV from an HP of  –100 
mV in 10 mV increments at 15-second intervals.
Electrophysiological data were compiled and analyzed using Clampfit 10.3 (Molecular Devices) and 
GraphPad Prism.
Quantitative reverse-transcription PCR. Total RNA (2 μg) isolated from individual matched (n = 6) human 
right atria, left atria, RV, and LV tissue samples was reverse-transcribed into cDNA with a high-capacity 
cDNA kit. Transcript analysis was conducted with SYBR green using a 7900HT Fast Real-Time PCR 
system (all from Applied Biosystems, Thermo Fisher Scientific). Data were analyzed using the Ct relative 
quantification method using the GAPDH and hypoxanthine guanine phosphoribosyl transferase I (HPRT) 
genes as endogenous controls.
Statistics. Results are presented as mean ± SEM. The number of  animals and the number of  cells used 
in each experiment are provided in the figure legends. Comparisons of  differences between WT and Scn1b-
null cells/animals under control conditions and before and after drug treatments were performed using a 
paired 2-tailed Student’s t test (Microsoft Excel). In comparisons of  more than 2 groups, 1-way ANOVA 
was used followed by multiple comparisons. The P values shown were corrected for multiple hypothesis 
testing using Dunnett’s correction method. P values less than 0.05 were considered significant.
Study approval. All animals were handled in accordance with the NIH Guide for the Care and Use of  
Laboratory Animals, and all experimental protocols were approved by the Washington University IACUC.
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